Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Show

For a long time, the tirzepatide-vs-semaglutide debate was an exercise in comparing trials that weren't really comparable — different patient populations, different trial designs, different eras. People would point to one drug's weight-loss numbers next to the other's and call it a comparison, when it wasn't really one. SURMOUNT-5 changed that. It's the first randomized trial to put both drugs head-to-head in the same population, at the same time, and it gave a real answer. The Mechanism Difference Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist — it mimics one gut hormone that regulates appetite and blood sugar. Tirzepatide (Mounjaro/Zepbound) is a dual agonist, hitting both GLP-1 and GIP receptors. The GIP receptor's role in fat tissue appears to matter here: when GIP and GLP-1 receptors are activated together, the effect on fat mobilization and energy expenditure appears to be more than additive, which is the leading explanation for why tirzepatide has consistently outperformed semaglutide across trials. What SURMOUNT-5 Actually Found SURMOUNT-5 was a randomized, open-label Phase 3b trial that enrolled 751 adults with obesity or overweight (without diabetes) and randomized them to either tirzepatide or semaglutide at each drug's maximum tolerated dose, followed for 72 weeks. The result: tirzepatide produced a mean body weight reduction of 20.2%, compared to 13.7% for semaglutide — roughly 47% greater relative weight loss. Tirzepatide also came out ahead on every key secondary endpoint measured, including the percentage of participants reaching more aggressive weight-loss thresholds: 31.6% of the tirzepatide group lost at least 25% of their body weight, compared to 16.1% on semaglutide. Waist circumference reductions followed the same pattern. A follow-up post-hoc analysis of the same trial data went a step further, projecting 10-year cardiovascular disease risk reduction between the two drugs using the trial's patient-level data — the first attempt at a direct, single-trial comparison of long-term cardiovascular benefit between the two, rather than inferring it from separate trials. The Caveats Worth Knowing Two things are worth keeping in mind before treating this as the final word. First, SURMOUNT-5 was open-label — both participants and researchers knew which drug each person was taking. That's a real limitation; it doesn't undermine an objective measurement like body weight, but it's a different standard of evidence than a fully blinded trial. Second, this was funded and run by Eli Lilly, tirzepatide's manufacturer — not necessarily a reason to doubt the data (the trial design and endpoints were pre-registered and the results were published in the New England Journal of Medicine), but it's a relevant piece of context, as it would be for any single-sponsor head-to-head trial. Side Effects: Roughly Similar Profile Both drugs share the same class-typical side effect profile — primarily gastrointestinal issues (nausea, digestive discomfort), especially during dose escalation. SURMOUNT-5 didn't show a dramatically different tolerability picture between the two; the meaningful difference in this trial was efficacy, not safety. Where This Leaves the Comparison For weight loss specifically, SURMOUNT-5 is about as clean an answer as this kind of question gets: in a real head-to-head trial, tirzepatide produced meaningfully greater weight loss than semaglutide, in the same population, under the same conditions. That's a genuine, well-supported finding — but "more weight loss" and "better choice for a given person" aren't automatically the same thing. Cost, insurance coverage, individual tolerability, and other health conditions all factor into that decision in ways a single trial can't settle, which is exactly the kind of judgment call worth making with a prescribing physician rather than a blog post. The Bottom Line The tirzepatide-vs-semaglutide efficacy question has a real answer now, and it's tirzepatide, at least for weight loss in this population. What SURMOUNT-5 doesn't answer — and what remains genuinely individual — is which drug makes sense for a particular person's health profile, budget, and tolerance for side effects.